Highlights Revelation Biosciences, Inc.

Equities

REVB

US76135L5075

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-10 pm EDT			5-day change	1st Jan Change
2.06 ^USD	-6.36%		-13.08%	-86.29%

Mar. 22	Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Mar. 22	Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 22	CI
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini	Mar. 04	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday on Unchanged Fed Rate, Upcoming Earnings	Feb. 01	MT
Revelation Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Revelation Biosciences Inc. Announces Data from Recent Preclinical Studies of the Gemini Formulation Demonstrates Its Therapeutic Potential as A Preventative Therapy Across Multiple Indications Including Infection and Acute Kidney Injury	23-10-12	CI
Revelation Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress	23-03-30	BU
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board	23-03-13	BU
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering	23-02-13	BU
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering	23-02-09	BU
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300	23-02-07	BU
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300	23-02-07	CI
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders	23-01-31	BU
Revelation Biosciences : Announces Pricing of Upcoming Automatic Unit Separation - Form 8-K	23-01-10	PU
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023	23-01-10	BU
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model	22-11-18	BU
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition in Preclinical Model	22-11-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Revelation Biosciences, Inc.

Equities

REVB

US76135L5075

Highlights

Filters